Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 9/20 | 0.70 |
| ▸ | RARB | P10826 | 9/20 | 0.70 |
| ▸ | RARG | P13631 | 8/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671213 | 0.90 | CYP3A4 (0.61) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL8559730 | 0.89 | RARB (0.54) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL1078963 | 0.88 | CYP3A4 (0.60) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL9270697 | 0.87 | CYP3A4 (0.77) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL1320433 | 0.87 | CYP3A4 (0.65) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL7656508 | 0.86 | CYP3A4 (0.58) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6668066 | 0.86 | RARA (0.57) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6668831 | 0.85 | RARA (0.56) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL7652569 | 0.85 | CYP3A4 (0.56) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL8626930 | 0.85 | CYP3A4 (0.65) | RARARARBRARGCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0785782-B1 | USE OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-0785782-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | Allergan (US) | 1997-07-30 | — | — | EP | claimed |
| US-5602130-A | ORNITHINE DECARBOXYLASE ENZYME INHIBITOR TREATING SKIN DISORDER, INHIBITING CELL HYPERPROLIFERATION | ALLERGAN | 1997-02-11 | — | — | US | claimed |
| WO-1996011686-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0284288-B1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1992-05-27 | — | — | EP | claimed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | claimed |
| EP-0284288-A1 | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | claimed |
| US-20120328670-A1 | Targeted Delivery of Retinoid Compounds to the Sebaceous Glands | ALLERGAN, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012167018-A1 | TARGETED DELIVERY OF RETINOID COMPOUNDS TO THE SEBACEOUS GLANDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20110076318-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS | ALLERGAN, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20090163550-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS | ALLERGAN, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1765284-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS AND RELATED METHODS OF MANUFACTURING | Allergan, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-05-18 | — | — | US | disclosed |
| US-5348972-A | In treatment of skin disorders such as acne and psoriasis | ALLERGAN, INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5234926-A | Skin disorders | ALLERGAN, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0284288-B1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | disclosed |
| US-5053523-A | Chemical intermediate for compounds having retinoic acid-like activity | ALLERGAN, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076318-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS | RARG, RARB, RARA | RARA 3/4885RARB 2/4885RARG 1/4885 |
| US-20120328670-A1 | Targeted Delivery of Retinoid Compounds to the Sebaceous Glands | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
| US-20090163550-A1 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS | RARB, RARG, RARA | RARA 3/4885RARB 1/4885RARG 2/4885 |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | CBR3, NR1H2, NR3C2 | RARA 2569/4885RARB 2140/4885RARG 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.